Between 2 and 9 percent of women of...

Between 2 and 9 percent of women of reproductive age experience methodical symptoms during the luteal phase of the menstrual circle of time that meet criteria for premenstrual dysphoric disorder (PMDD) The management of these women remains highly controversial, if it were not that treatment with antidepressants has been consistently effective. mostly evidence exists for the selective serotonin reuptake inhibitors (SSRIs) fluoxetine and sertraline. Because patients merely have symptoms intermittently and usually be agreeable to rapidly to SSRI therapy, intermittent rather than continuous SSRI treatment has been advocated. Halbreich and colleagues studied the consequence of intermittent sertraline in 281 women who met criteria for cruel PMDD.

Patients 24 to 45 years of age were recruited at advertisement and referral to 14 psychiatric or gynecologic center in the United States and Canada. Patients were required to have had regular menstrual circle of times and to have reported PMDD symptoms for at least brace years. The diagnosis was confirmed by the agency of the standardized Daily Record of Severity of question at issues for two consecutive menstrual periods showing scores at least 75 percent higher during the five chiefly symptomatic days in the week before mense compared with the midfollicular phase.

Patients with high scores in succession depression screening and those using oral contraceptives were exclud from the contemplation Other reasons for exclusion included history of significant psychiatric illness, use of antidepressants, and anovulatory state, including women who had undergone hysterectomy. All patients had previously corresponded adequately to treatment of their PMDD with antidepressants.

After all patients initially complet the same cycle of placebo treatment, solely those whose symptoms continued and who demonstrated compliance were come intoed into the final study. The 142 women randomly allocated to sertraline therapy began with 50 mg daily upon the 14 days before the anticipated assault of bleeding. Physicians could increase the dosage to 100 mg by day if clinically indicated. All patients complet the Daily Record of Severity of moot points throughout the three cycles of the study

The treated patients were comparable to those receiving placebo in all relevant variables. The typical patient was white, 36 years of age, well educated, married with undivided or two children, and had a mean circle of time length of 27.5 days. Before treatment, the mean severity scores were 73 during the luteal phase and 31 in the midfollicular phase.

Women taking sertraline improved more than those taking placebo in the first round of years of treatment and sustained improvement for all three circle of times monitored. The improvement was statistically significant in all measures of depression and anxiety and in the Daily Record of Severity of question at issues Women receiving sertraline did not display significantly greater improvement in physical symptoms similar as headache, breast tenderness, or bloating when compared with women receiving placebo. Nevertheless, measures of the unadulterated impact on daily life showed significant advantage for sertraline treatment. by the agency of the third cycle, 63 percent of the patients taking sertraline and 46 percent of those taking placebo had scored within 10 percent of community norms for measures of life satisfaction. Women taking sertraline reported more headache, nausea, thirsty mouth, insomnia, and diarrhea than those taking placebo, and 8 percent discontinued sertraline therapy because of side effects

The authors bring to an end that using sertraline during the luteal phase provides effective relief of PMDD symptoms. This inference correlates with other studies suggesting that intermittent therapy with SSRIs can be effective in women with this condition.

EDITOR'S NOTE: not many topics are more controversial or more difficult to treat objectively than the various stamps of premenstrual syndrome (PMS). The authors of this paper have published extensively forward the topic and are well-known advocates for vigorous treatment of all the manifestations of PM All of the measures used, although validated, hang on subjective reports by patients or clinicians. With gooded patients and enthusiastic, expert clinicians, the placebo efficiency is powerful and is unlikely to be replicable in everyday practice. The placebo assign places tos in this study achieved significant improvements through the whole extent of baseline. Nevertheless, even in this same select situation, the reported mean gains in measures have wide ranges, indicating that individual women had excessively different experiences. What is the "bottom line" for us in practice? Probably that we do not have excellent treatments for every woman who has premenstrual symptoms unless that empathic objective approaches are beneficial and that we ne to pay almost as a great deal attention to how we negotiate treatments for individual women as to what we make acceptable Very few of the instant therapies can be supported according to systematic evidence-based reviews, but short courses of selective serotonin reuptake inhibitors each month could be useful in any women.--A.D.W.